MedTrace Logo

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

NCT00514540 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2020-09-01

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn about how effective 2 chemotherapy drugs carboplatin (Paraplatin) plus docetaxel (Taxotere) in the treatment of patients with anaplastic prostate cancer. Patients who continue to have advanced disease will be switched to etoposide (VePesid) plus cisplatin (Platinol-AQ) to study how effective this second line of chemotherapy is in the treatment of patients iwth anaplastic prostate cancer.

The side effects, characteristics of patients who respond, and overall survival will also be studied.

Conditions

Interventions

DRUG

Docetaxel

75 mg/m\^2 IV over 60 Minutes on Day 1 of 21 day cycle.

DRUG

Carboplatin

AUC = 5 IV Over 30 Minutes On Day 1 of 21 day cycle.

DRUG

Etoposide

120 mg/m\^2 daily for 3 days of 21 day cycle.

DRUG

Cisplatin

25 mg/m\^2 for 3 days of 21 day cycle.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Ana M. Aparicio, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00514540 on ClinicalTrials.gov